Adverse cardiac events associated with antibody-drug conjugates in cancer patients: retrospective analysis of FAERS database and RCTs

医学 不利影响 内科学 不良事件报告系统 随机对照试验 药品 回顾性队列研究 癌症 肿瘤科 数据库 药理学 计算机科学
作者
Shaowei Zhuang,Bitao Wang,EX Wu,Jierong Lin,Wanxian Zeng,Maobai Liu,Jing Yang,Xiujuan Zhang
出处
期刊:Cardiovascular Research [Oxford University Press]
卷期号:121 (15): 2318-2333 被引量:5
标识
DOI:10.1093/cvr/cvaf095
摘要

Antibody-drug conjugates (ADCs) are approved for use in cancers. Cardiovascular adverse reaction is a fatal adverse reaction associated with ADCs. The incidence of adverse cardiac events about ADCs has not been fully studied. We aimed to assess differences in cardiotoxicity among cancer patients treated with different ADCs. An observational retrospective pharmacovigilance study of ADC-related adverse cardiac events was conducted based on the FDA Adverse Event Reporting System (FAERS) and Open tools for data mining and analysis of pharmacoVigilance data (OpenVigil 2.1) website. We conducted a comprehensive search of articles published before 24 January 2024, using PubMed, Web of Science, Cochrane Library, Scopus, CINAHL, Embase databases, and the Clinical Trials website (https://clinicaltrials.gov). Primary outcomes include any cardiotoxicity. Secondary outcomes focused on heart failure. Network meta-analysis and subgroup analyses were conducted to synthesize results based on relative risk (RR) values. Surface under the cumulative ranking curve (SUCRA) values were calculated for risk ranking among ADCs according to the types and target of ADCs. A total of 1522 cases of cardiac adverse events from FAERS associated with ADC treatments. All ADCs showed disproportionate association in cardiac adverse events. Gender and age factors are considered to have an influential role in the cardiotoxicity induced by ADCs. The network meta-analysis showed that the overall incidence rate was 17.12% [95% confidence interval (CI): 13.36%, 20.88%]. Brentuximab vedotin has the RR value of 1.78 (95% CI: 1.13, 2.82). HER-2-targeted ADCs have the RR value of 0.61 (95% CI: 0.42, 0.89). Polatuzumab vedotin and enfortumab vedotin have SUCRA values of 82.6 and 22.0, respectively. The SUCRA values of ADC targeting FRα and TROP-2 were 75.6 and 18.8, respectively. Cardiac adverse events are associated with ADCs. ADCs targeting HER-2 show lower cardiac toxicity. Brentuximab vedotin is associated with higher cardiac toxicity. Polatuzumab vedotin has the highest risk for cardiac toxicity, and enfortumab vedotin has the lowest risk. ADC targeting FRα has the highest risk of cardiotoxicity, and ADC targeting TROP-2 has the lowest risk.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Hh完成签到,获得积分10
1秒前
ffffwj2024完成签到,获得积分10
1秒前
研友_X89o6n完成签到,获得积分10
1秒前
小王发布了新的文献求助10
1秒前
生动的乐曲完成签到,获得积分10
1秒前
2秒前
生动的访琴完成签到,获得积分10
2秒前
r12r1完成签到,获得积分10
3秒前
姜姜完成签到,获得积分10
3秒前
throb发布了新的文献求助10
3秒前
零零1完成签到 ,获得积分10
4秒前
碎觉觉发布了新的文献求助10
5秒前
6秒前
6秒前
6秒前
Nuyoah完成签到 ,获得积分10
7秒前
转复窦律完成签到,获得积分10
7秒前
粗犷的翎完成签到,获得积分10
7秒前
可爱安荷发布了新的文献求助10
8秒前
10秒前
cyy完成签到,获得积分10
10秒前
10秒前
啊汪~发布了新的文献求助10
12秒前
13秒前
throb完成签到,获得积分10
13秒前
大模型的应助被七听采纳,获得10
13秒前
方圆完成签到 ,获得积分10
15秒前
15秒前
遇见完成签到,获得积分20
16秒前
16秒前
2275523154完成签到,获得积分10
16秒前
千里清秋完成签到,获得积分10
16秒前
quan完成签到,获得积分10
16秒前
美宁完成签到,获得积分10
18秒前
顺利的妖妖完成签到 ,获得积分10
19秒前
再睡十分钟完成签到 ,获得积分10
19秒前
penicillin完成签到 ,获得积分10
19秒前
辛勤以柳发布了新的文献求助10
21秒前
敏感的傲云完成签到,获得积分10
21秒前
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190478
求助须知:如何正确求助?哪些是违规求助? 9577686
关于积分的说明 21853808
捐赠科研通 7789496
什么是DOI,文献DOI怎么找? 3436407
关于科研通互助平台的介绍 2560235
邀请新用户注册赠送积分活动 2483054